ICVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ICVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Icosavax has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Icosavax's Operating Margin % for the quarter that ended in Sep. 2023 was %. As of today, Icosavax's Piotroski F-Score is 2.
For the Biotechnology subindustry, Icosavax's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Icosavax's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Icosavax's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Icosavax has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Icosavax's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:
Operating Margin % | = | Operating Income (Q: Sep. 2023 ) | / | Revenue (Q: Sep. 2023 ) |
= | -25.275 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Icosavax has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Icosavax's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Adam K. Simpson | director, officer: Chief Executive Officer | C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102 |
Niranjan Kanesa-thasan | officer: Chief Medical Officer | 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102 |
Cassia Cearley | officer: Chief Business Officer | 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102 |
Thomas Joseph Russo | officer: Chief Financial Officer | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032 |
Douglas Holtzman | officer: Chief Scientific Officer | 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102 |
Amin Khan | officer: EVP, Head of Research & Dev. | C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155 |
Ra Capital Nexus Fund, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Elizabeth Bekiroglu | officer: See Remarks | 1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793 |
Charles E Richardson | officer: See Remarks | 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102 |
Jim Wassil | director | C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
John W. Shiver | director | C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102 |
Anofi | 10 percent owner | 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017 |
Nanodimension Iii, L.p. | 10 percent owner | GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
From GuruFocus
By PRNewswire • 12-20-2023
By GuruFocus Research • 12-24-2023
By Value_Insider Value_Insider • 11-08-2022
By Stock market mentor Stock market mentor • 01-06-2023
By sperokesalga sperokesalga • 02-21-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By Business Wire • 12-15-2023
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire • 12-12-2023
By GuruFocus Research • 11-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.